Infant Mortality, Maternal Mortality, Vitamin A Deficiency
Conditions
Keywords
Maternal mortality, Infant mortality, Vitamin A, Beta-carotene, Micronutrients, Bangladesh, Neonatal mortality
Brief summary
The purpose of this trial is to determine whether providing women with a weekly oral supplement of vitamin A, either preformed or as beta-carotene, at a dosage equivalent to a recommended intake from early pregnancy through three months postpartum, can reduce the risk of maternal mortality, fetal loss, or infant mortality.
Detailed description
Maternal mortality and vitamin A deficiency coexist in rural South Asia. In Nepal, weekly supplementation with vitamin A or beta-carotene during the child-bearing years reduced all-cause maternal mortality and, in night blind women, also infant mortality. The present trial is testing the efficacy of the same supplements from \ 9 weeks' gestation to 12 weeks postpartum. The planned sample size is 68,000 pregnancies. It is being conducted in 19 rural unions, covering an area of \ 750 sq km with a population of \ 580,000 in Gaibandha and Southern Rangpur Districts in Northern Bangladesh. The study area was mapped as 596 sectors (unit of randomization), each comprising 200-275 households; \ 135,000 houses were numerically addressed and, at the outset, 103,000 women were listed. Women are visited at home every 5 weeks by 596 trained female staff to detect pregnancy by a combination of menstrual history and urine testing. Newly married women are prospectively enlisted for pregnancy surveillance. Following informed consent urine-positive (pregnant) women detected during surveillance are enrolled to receive weekly a capsule containing 7000 retinol equivalents of preformed vitamin A, 42 mg of beta-carotene or placebo. Vital events are recorded weekly through 3 months postpartum. Trained interviewers conduct maternal nutritional and health and household socioeconomic assessments in the 1st trimester. At 3 months postpartum, interviewers assess both mother and infant for health and nutritional status, including apparent birth defects that are later physician-confirmed. An additional home health assessment occurs at 6 months post partum, and vital status is recorded for mother and infant at one year postpartum. A \ 3% subsample of enrolled pregnant women participate in a substudy involving enhanced clinical, anthropometric, biochemical, body compositional, morbidity and interview-based assessment protocols in the 1st, 2nd and 3rd trimesters, and at 3 months post-partum. Reported maternal and infant deaths are verified and causes ascertained during verbal autopsy interviews with family members of the deceased.
Interventions
weekly dosage of either 7000 µg retinol equivalents as preformed vitamin A or 42 mg of beta-carotene from 1st trimester of pregnancy through 12 weeks after termination of pregnancy
Sponsors
Study design
Eligibility
Inclusion criteria
* Married women of reproductive age * First pregnancy during time period of trial
Exclusion criteria
* Premenarchial girls * Married women with a previous pregnancy enrolled into the trial * Previously married women who have moved into the study area * Single women (never married, widowers) * Women who are sterilized (or whose husbands are sterilized) * Menopausal women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| All-cause, Pregnancy-related Mortality | Deaths during pregnancy through 12 weeks postpartum | Mortality evaluated on intent-to-treat basis |
Secondary
| Measure | Time frame |
|---|---|
| Maternal Morbidity, Including Obstetric Complications | through the 1st 24 weeks following termination of pregnancy |
| Gestational Age at Birth | within 24 weeks after birth |
| Fetal Growth and Postnatal Infant Growth Through Three Months of Age | through the 1st 12 weeks after birth |
| All-cause 3-month Infant Mortality | Deaths through the 1st 12 weeks of life |
| Plasma Beta-carotene in the Third Trimester of Pregnancy(Nutritonal Status of the Mother) | Third trimester of pregnancy (about the 32nd week of gesatation) |
| Plasma Retinol at the Third Trimester of Pregnancy (Nutritional Status of the Mother) | Third trimester of pregnancy (about the 32nd week of gestation) |
| Infant Morbidity Through 3 Months of Age | within 24 weeks after birth |
Countries
Bangladesh, United States
Participant flow
Recruitment details
Women were recruited into the trial from August 2001 to January 2007. As this was a community trial, we identified pregnant women by conducting a urine test on women reporting to be amenstrual from the last visit during 5 weekly visit cycles to their homes in rural communities of the districts of Rangpur and Gaibandha, Bangladesh.
Participants by arm
| Arm | Count |
|---|---|
| 1 Placebo Control Weekly oral supplement with placebo from early pregnancy through 12 weeks following termination of pregnancy | 19,862 |
| 2 Vitamin A Supplement Weekly oral supplement with 7000 micrograms of retinol equivalents from early pregnancy through 12 weeks following termination of pregnancy | 19,806 |
| 3 Beta-Carotene Group Weekly oral supplement with 42 mg of all-trans beta-carotene from early pregnancy through 12 weeks following termination of pregnancy | 19,998 |
| Total | 59,666 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Lost to Follow-up | 14 | 20 | 21 |
Baseline characteristics
| Characteristic | 2 Vitamin A Supplement | 3 Beta-Carotene Group | 1 Placebo Control | Total |
|---|---|---|---|---|
| Age Categorical <=18 years | 5774 participants | 5936 participants | 5875 participants | 17585 participants |
| Age Categorical >=65 years | 0 participants | 0 participants | 0 participants | 0 participants |
| Age Categorical Between 18 and 65 years | 14017 participants | 14056 participants | 13973 participants | 42046 participants |
| Age Continuous | 23.17 years STANDARD_DEVIATION 6.56 | 23.06 years STANDARD_DEVIATION 6.56 | 23.03 years STANDARD_DEVIATION 6.53 | 23.09 years STANDARD_DEVIATION 6.55 |
| Region of Enrollment Bangladesh | 19806 participants | 19998 participants | 19862 participants | 59666 participants |
| Sex: Female, Male Female | 19806 Participants | 19998 Participants | 19862 Participants | 59666 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 0 / 0 | 0 / 0 | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 | 0 / 0 | 0 / 0 |
Outcome results
All-cause, Pregnancy-related Mortality
Mortality evaluated on intent-to-treat basis
Time frame: Deaths during pregnancy through 12 weeks postpartum
Population: As the study ended on the advice of the Data and Safety Monitoring Board, based on evidence of no difference, all enrolled women who had a chance of being followed through 84 days after the end of their pregnancy were included in the trial. The cohort included pregnancies identified between August 17, 2001 and January 5, 2006.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 1 Placebo Control | All-cause, Pregnancy-related Mortality | 41 Participants |
| 2 Vitamin A Supplement | All-cause, Pregnancy-related Mortality | 47 Participants |
| 3 Beta-Carotene Group | All-cause, Pregnancy-related Mortality | 50 Participants |
All-cause 3-month Infant Mortality
Time frame: Deaths through the 1st 12 weeks of life
Population: Mortality evaluated on intent-to-treat basis
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 1 Placebo Control | All-cause 3-month Infant Mortality | 951 participants |
| 2 Vitamin A Supplement | All-cause 3-month Infant Mortality | 904 participants |
| 3 Beta-Carotene Group | All-cause 3-month Infant Mortality | 979 participants |
Fetal Growth and Postnatal Infant Growth Through Three Months of Age
Time frame: through the 1st 12 weeks after birth
Gestational Age at Birth
Time frame: within 24 weeks after birth
Infant Morbidity Through 3 Months of Age
Time frame: within 24 weeks after birth
Maternal Morbidity, Including Obstetric Complications
Time frame: through the 1st 24 weeks following termination of pregnancy
Plasma Beta-carotene in the Third Trimester of Pregnancy(Nutritonal Status of the Mother)
Time frame: Third trimester of pregnancy (about the 32nd week of gesatation)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| 1 Placebo Control | Plasma Beta-carotene in the Third Trimester of Pregnancy(Nutritonal Status of the Mother) | 0.11 Plasma beta-carotene micromoles / liter | Standard Deviation 0.09 |
| 2 Vitamin A Supplement | Plasma Beta-carotene in the Third Trimester of Pregnancy(Nutritonal Status of the Mother) | 0.12 Plasma beta-carotene micromoles / liter | Standard Deviation 0.12 |
| 3 Beta-Carotene Group | Plasma Beta-carotene in the Third Trimester of Pregnancy(Nutritonal Status of the Mother) | 0.12 Plasma beta-carotene micromoles / liter | Standard Deviation 0.1 |
Plasma Retinol at the Third Trimester of Pregnancy (Nutritional Status of the Mother)
Time frame: Third trimester of pregnancy (about the 32nd week of gestation)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| 1 Placebo Control | Plasma Retinol at the Third Trimester of Pregnancy (Nutritional Status of the Mother) | 1.02 micromoles per liter | Standard Deviation 0.31 |
| 2 Vitamin A Supplement | Plasma Retinol at the Third Trimester of Pregnancy (Nutritional Status of the Mother) | 1.25 micromoles per liter | Standard Deviation 0.33 |
| 3 Beta-Carotene Group | Plasma Retinol at the Third Trimester of Pregnancy (Nutritional Status of the Mother) | 1.06 micromoles per liter | Standard Deviation 0.33 |